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Abstract
Background: Hepatoma arterial-embolization prognostic (HAP) score and its modifications (modified HAP [mHAP]
and mHAP-II), consisting of some or all of the following factors of tumor size, number, alpha-fetoprotein, bilirubin,
and serum albumin, have been found to predict outcomes after trans-arterial chemoembolization (TACE) for
hepatocellular carcinoma (HCC). We investigated the feasibility of using HAP-related risk scores for dynamic risk
assessment during repeated TACE.
Methods: A total of 619 HCC patients treated with TACE from two institutions between 2003 and 2010 were
included.
Results: Patients with A-B class risk scores showed significantly better survival than those with C-D class risk scores
at the first (median 43.7 vs. 21.5 months for mHAP-II, 35.2 vs. 10.2 months for mHAP, and 39.8 vs. 18.6 months for
HAP; all P < 0.001) and the second rounds of TACE (38.6 vs. 17.2 months for mHAP-II, 30.0 vs. 8.5 months for mHAP,
and 32.6 vs. 17.3 months for HAP; all P < 0.001). Sequential assessment of risk scores at the second TACE round was
applied for patients with A-B class risk scores at the first TACE round, which further identified two subgroups of A-B
and C-D class risk scores with different outcomes (median survival 40.6 vs. 19.6 months for mHAP-II, 31.2 vs. 16.9
months for mHAP, and 35.8 vs. 21.0 months for HAP; all P < 0.001). Compared with mHAP and HAP, mHAP-II
showed the highest likelihood ratio (22.61 vs. 14.67 and 13.97, respectively), highest linear trend (24.43 vs. 19.67 and
14.19, respectively), and lowest Akaike information criteria value (1432.51 vs. 3412.29 and 2296.98, respectively).
Conclusions: All HAP-related risk scores dynamically predicted outcomes during repeated TACE. Sequential risk
assessment using mHAP-II best identified optimal candidates for repeated TACE.
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Background
Despite the availability of curative treatment modalities,
such as liver transplantation, surgical resection, and ra-
diofrequency ablation, the outcomes of patients with he-
patocellular carcinoma (HCC) remain poor. This is
because most HCC patients are not suitable candidates
for these curative treatments, due to their advanced dis-
ease stage and poor liver function at the time of diagno-
sis [1, 2]. Accordingly, non-curative treatments, such as
trans-arterial chemoembolization (TACE), radioemboli-
zation, and sorafenib, are used in patients with advanced
HCC [3–5].
Based on the survival advantages of TACE, compared
to best supportive care, reported in randomized trials
and a subsequent systematic review [6–8], international
guidelines have recommended TACE for patients with
HCC of Barcelona Clinic Liver Cancer (BCLC) inter-
mediate stage (B) or those with early stage disease who
are not candidates for percutaneous ablation, liver resec-
tion, or transplantation [9]. However, differences in sur-
vival have been reported among a series of patients
treated with TACE [10], probably because of the hetero-
geneity of liver function and the tumor burden among
patients of the same disease stage. Thus, as proposed in
previous studies [11, 12], it is important to select candi-
dates who will benefit from TACE.
Hepatoma arterial-embolization prognostic (HAP)
score, which consists of four tumor-related variables
(alpha-fetoprotein [AFP] level and tumor size) and liver
function-related variables (serum albumin and total bili-
rubin levels), has been proposed for predicting outcomes
after TACE [13]. In addition, two modifications of HAP
score have been proposed: modified HAP score (mHAP),
which excludes total bilirubin from the HAP score [14],
and mHAP-II score, in which tumor number is a con-
stituent variable [15].
The above HAP-related risk scores have been shown
to provide acceptable accuracy in risk assessment of pa-
tients with HCC treated with TACE. However, because
HAP-related risk scores comprise values determined at
the time of the initial TACE and because remnant tumor
burden and liver function can change after each TACE
session, their dynamic prognostic performance needs to
be confirmed. Thus, we evaluated the feasibility of dy-
namic risk assessment using HAP-related risk scores
during repeated TACE rounds in patients with HCC and
compared their prognostic performance.
Methods
Patient eligibility
Consecutive treatment-naïve patients diagnosed with
HCC treated with TACE as a first-line therapy from
2003 to 2009 (Liver Center, Severance Hospital, Yonsei
University College of Medicine) and 2003 to 2010 (Liver
Center, Guro Hospital, Korea University of College of
Medicine) were included in this retrospective multicen-
ter cohort study.
The exclusion criteria were 1) inadequate target lesion
with infiltrative pattern, non-arterial enhancement, or
the largest lesion less than 1 cm; 2) presence of primary
malignancy in another organ; 3) tumor invasion to the
main portal vein or presence of extrahepatic tumor le-
sions; 4) Child-Pugh class C; 5) BCLC stage D, 6) pres-
ence of uncontrolled functional or metabolic diseases,
and 7) TACE as a bridge to transplantation (Add-
itional file 1: Figure S1).
The study protocol was designed in accordance with
the ethics guidelines of the 1975 Declaration of Helsinki,
and the study was approved by the institutional review
boards of Severance Hospital and Korea University Guro
Hospital. Written informed consent was not acquired
because this study was a retrospective study.
Diagnosis and staging of HCC
HCC diagnosis was made based on the guidelines pro-
posed by the Korea Liver Cancer Study Group [16].
Tumor staging was assessed using the BCLC staging sys-
tem [17].
TACE procedure and follow-up
Detailed information on the TACE procedure has been
described in a previous study [15]. Briefly, after angiog-
raphy of the superior mesenteric and hepatic arteries,
conventional TACE was performed by selective infusion
of a mixture of 5 mL of iodized oil contrast medium
(lipiodol; Guerbet) and either 50 mg of adriamycin or
cisplatin at 2 mg/kg body weight, followed by
embolization using gelatin sponge particles with a diam-
eter of 1 mm (Cutanplast; Mascia Bruneili, S.p.a.).
Super-selective embolization was performed using a
2.0-Fr microcatheter (Progreat alpha; Terumo).
Embolization was performed until stasis was achieved.
A contrast-enhanced CT or MRI of the liver was per-
formed at 4 to 6 weeks after TACE to assess the effect of
embolization on the tumor. The radiologic response to
TACE was based on the modified Response Evaluation
Criteria in Solid Tumors (mRECIST) on CT or MRI [3,
4]. In patients with a residual arterially enhancing viable
tumor, TACE was repeated at 6- to 8-week intervals, if
clinically indicated. In patients with complete tumor ne-
crosis, a contrast-enhanced CT or MRI was repeated
every 3 to 6 months [3, 4]. In patients who were not can-
didates for repeated TACE, alternative treatment was
performed at the physician’s discretion. The TACE pro-
cedures and follow-up protocols were largely the same
between two institutions, and there was no major
change in TACE practice during the study period.
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Study design
After pooling patient data from the two institutions, the
study population was divided into a group with favorable
expected outcomes (A-B class for three risk scores) and
one with unfavorable expected outcomes (C-D class for
three risk scores) at each TACE. The detailed scoring
systems of HAP-related risk scores are summarized in
Additional file 2: Table S1 [13–15]. Then, since we previ-
ously showed that mHAP-II score, as well as HAP and
mHAP scores, predicted survival outcomes for
treatment-naïve patients with HCC treated with TACE,
we validated the prognostic performance of HAP-related
risk scores during repeated TACE (A-B vs. C-D class
HAP-related risk scores at the first and second TACE
rounds). Next, we investigated whether the sequential
use of HAP-related risk scores during repeated TACE
held any prognostic value (A-B class risk score at the
first TACE→A-B class risk score at the second TACE vs.
A-B class risk score at the first TACE→C-D class risk
score at the second TACE vs. C-D class risk scores at
the first TACE). Measurement of tumor sizes for
HAP-related scores after repeated TACE was based on
mRECIST [3, 4]. Finally, we investigated the most appro-
priate risk score with which to determine subgroups
with different prognoses when the sequential use of risk
scores was applied during repeated TACE (Add-
itional file 3: Figure S2).
Statistical analysis
Baseline patient and tumor characteristics are presented
as the median (interquartile range; IQR) or n (%), as ap-
propriate. The Mann-Whitney test and Fisher’s exact
test were used to compare characteristics between the
two institutes, as appropriate. Survival was defined as
the time from the date of each TACE until the date of
death or last follow up. Survival curves were plotted
using the Kaplan-Meier method, and median survival
times with their 95% confidence intervals (CIs) are re-
ported. The log-rank test was used to compare the sur-
vival difference between the groups.
Variables including components of HAP-related risk
scores were evaluated using univariate and multivariate
Cox regression analyses to identify predictive factors for
survival. Variables with P < 0.05 in the univariate analysis
were included as candidate variables in the multivariate
Cox regression analysis to identify independent predic-
tors of survival in the respective TACE sessions. The ad-
justed hazard ratios (HRs) and 95% Cis for variables
were also calculated. The prognostic performance of
HAP-related risk scores at the first and the second
rounds of TACE was assessed using areas under
receiver-operating curves (AUROCs) to predict mortality
at 1 to 5 years of follow up. A comparison between
AUROCs was made using the DeLong test.
To compare the homogeneity and discriminatory abil-
ity of HAP-related risk scores, the likelihood ratio test
and the linear trend test were used. Furthermore, Akaike
information criteria (AIC) were calculated to demon-
strate which HAP-related risk score was more explana-
tory and informative for risk assessment of survival (a
smaller AIC indicates the preferred risk score).
All values of P < 0.05 were considered to indicate stat-
istical significance. Data were analyzed using SPSS 20.0
for Windows (SPSS Inc., Chicago, IL) and MedCalc Soft-
ware (version 12.7.2, MedCalc Software bvba, Ostend,
Belgium).
Results
Baseline characteristics
A total of 677 treatment-naïve patients with HCC
treated with TACE as the first-line therapy were consid-
ered eligible (297 from Severance Hospital and 380 from
Guro Hospital). After excluding 58 patients according to
our exclusion criteria, 619 patients were included for
statistical analysis (275 from Severance Hospital and 344
from Guro Hospital) (Additional file 1: Figure S1 and
Additional file 2: Table S2).
The baseline characteristics and liver-related biochem-
ical tests of the study population at the first and second
TACE rounds are shown in Table 1. At the first TACE
round, the median age of the study population (489 men
and 130 women) was 59 years. The majority of HCCs
were related to hepatitis B virus (HBV) infection (n =
422, 68.2%). The majority of patients had well-preserved
liver function with a Child-Pugh class of A (n = 516,
83.4%). The median diameter of the largest measurable
lesion was 3.5 cm, and 285 (46.0%) patients had multi-
focal HCC lesions. Segmental portal vein invasion was
identified in 74 (12.0%) patients.
Of the study population, 514 (83%) patients underwent
additional TACE, and their characteristics at the second
TACE are shown in Table 1. Among these 514 patients
who underwent a second round of TACE, 396 did so be-
cause of a residual lesion or incomplete response to the
first TACE, whereas the others (n = 118) received second
TACE on an on-demand basis to treat recurred HCC.
The median interval between the first and second TACE
rounds among these patients was 43 days (range, 16–90
days).
Follow up and survival outcomes of the study population
By the end of the follow-up period, 457 of 619 (73.8%)
patients had died (185 from Severance Hospital and 272
from Guro Hospital). The median survival of the study
population was 30.0 (95% CI 26.8–33.2) months. The
survival rates at 1, 3, and 5 years after the first TACE
round was 76.7, 44.2, and 27.3%, respectively (Add-
itional file 4: Figure S3).
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Independent risk factors for mortality at the first and
second TACE
In univariate analysis, male gender (HR 1.29), Child-Pugh
class B (HR 1.56), BCLC stage B-C (HR 1.64), the five com-
ponents of mHAP-II score (HR 1.98 for tumor size > 7 cm;
HR 1.88 for tumor number ≥ 2; HR 1.62 for AFP > 400 ng/
mL; HR 1.29 for total bilirubin > 0.9mg/dL; and HR 1.51 for
serum albumin < 3.6 g/dL), and C-D class mHAP-II score
(HR 2.07) were significant risk factors associated with mor-
tality at the first TACE (all P < 0.05) (Additional file 2: Table
S3). At the second TACE, all of the above risk factors, except
male gender (P= 0.461) and total bilirubin (P= 0.066), also
significantly predicted mortality (Additional file 2: Table S3).
Upon multivariate analysis of the significant variables in
the univariate analysis, without BCLC stage and Child-Pugh
class to avoid potential bias due to multi-collinearity, the five
components of mHAP-II, including tumor size > 7 cm (HR
= 1.90), tumor number ≥ 2 (HR= 1.73), AFP > 400 ng/mL
(HR= 1.58), total bilirubin > 0.9mg/dL (HR= 1.31), and
serum albumin < 3.6 g/dL (HR= 1.45), at the first TACE in-
dependently predicted mortality (all P < 0.05) (Table 2). Simi-
larly, all constituent variables of mHAP-II score, except for
total bilirubin (P= 0.241), at the second TACE independently
predicted mortality (Table 2).
Survival outcomes according to A-B vs. C-D class risk
scores at the first and second TACE
Since C-D class risk scores significantly predicted mortality
in the univariate analysis and since the five components of
HAP-related risk scores were selected as independent risk
factors for mortality, we investigated survival outcomes ac-
cording to A-B vs. C-D class risk scores at the first and sec-
ond TACE.
At the first TACE (n = 619), patients with A-B class risk
scores showed significantly better median survival than
those with C-D class risk scores (43.7 [n = 283, 46%] vs.
21.5months [n = 336, 46%] for mHAP-II; 35.2 [n = 519,
84%] vs. 10.2months [n = 100, 16%] for mHAP; 39.8 [n =
394, 64%] vs. 18.6months [n = 225, 36%] for HAP; all P <
0.001) (Fig. 1a-c, Table 3, Additional file 3: Figure S2). The
significant survival differences according to A-B vs. C-D
class risk scores were also maintained at the second TACE
(n = 514) (all P < 0.001) (Fig. 1d-f, Table 3, Additional file
3: Figure S2). The survival rate at 1, 3, and 5 years after
the first and second rounds of TACE according to risk
scores are summarized in Table 3. The HRs for mortality
for C-D class risk scores were 2.01–2.73 at the first TACE
and 1.97–2.64 at the second TACE (Table 3).
Dynamic risk assessment using risk scores during
repeated TACE
Among the 283 patients with mHAP-II A-B risk scores at
the first TACE, 228 patients underwent a second TACE in
an on-demand manner. Of these, 185 (81%) and 43 (19%)
patients showed mHAP-II A-B risk scores and mHAP-II
C-D risk scores, respectively, at the second TACE (Add-
itional file 3: Figure S2). The median survival of patients with
mHAP-II A-B risk scores at the second TACE was signifi-
cantly better than that of patients with mHAP-II C-D risk
scores (40.6 vs. 19.6months; P < 0.001) (Fig. 2a, Table 4,
Table 1 Patient characteristics
Variables At the first TACE (n = 619) At the second TACE (n = 514)
Age (years) 59 (52–66) –
Male gender 489 (79.0) –
Etiology
HBV/ HCV/ others 422 (68.2)/ 90 (14.5)/ 107 (17.3) –
Child-Pugh class
A/ B 516 (83.4)/ 103 (16.6) 436 (84.8)/ 78 (15.2)
BCLC stage
0/ A/ B/ C 36 (5.8)/ 261 (42.2)/ 227 (36.7)/ 95 (15.3) 128 (24.9)/ 174 (33.9)/ 121 (23.5)/ 91 (17.7)
Tumor size (cm) 3.5 (2.1–6.5) 2.1 (1.3–4.0)
Tumor number
Unifocal/ multifocal 334 (54.0)/ 285 (46.0) 451 (87.7)/ 63 (12.3)
Alpha-fetoprotein (ng/mL)
≤400/ > 400 471 (76.1)/ 148 (23.9) 458 (89.1)/ 56 (10.9)
Segmental portal vein invasion 74 (12.0) 74 (14.4)
Total bilirubin (mg/dL) 0.9 (0.6–1.3) 1.0 (0.6–1.3)
Serum albumin (g/dL) 3.9 (3.4–4.2) 3.7 (3.3–4.1)
Variables are expressed as medians (interquartile range) or n (%)
TACE trans-arterial chemoembolization, HBV hepatitis B virus, HCV hepatitis C virus, BCLC Barcelona Clinic Liver Cancer
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Additional file 3: Figure S2). Similar findings were also ob-
served when mHAP and HAP were applied (Fig. 2b-c, Table
4, Additional file 3: Figure S2). The survival rates at 1, 3,
and 5 years for the A-B and C-D class risk scores at the
second round of TACE among patients who were catego-
rized with A-B class risk at the first TACE round are sum-
marized in Table 4.
When the study population was stratified into three
groups according to risk stratification at the first and sec-
ond rounds of TACE, as previously described (A-B class
risk score at the first TACE → A-B class risk score at the
second TACE vs. A-B class risk score at the first TACE→
C-D class risk score at the second TACE vs. C-D class risk
score at the first TACE), patients with C-D class risk
scores at the first TACE showed the highest risk of mor-
tality (HR 2.17–2.91) and those with A-B class risk scores
at the first TACE, but C–D class risk scores at the second
TACE showed intermediate risk (HR 1.84–2.28) when
compared with patients with A-B class risk scores at both
the first and second TACE rounds (Table 4).
Prognostic accuracy of the sequential use of risk scores
during repeated TACE
Among the studied risk scores, mHAP-II, compared with
mHAP and HAP, showed the highest homogeneity (likeli-
hood ratio, 22.61 vs. 14.67 and 13.97, respectively), highest
discriminatory ability (linear trend, 24.43 vs. 19.67 and 14.19,
respectively), and lowest AIC value (1432.51 vs. 3412.29 and
2296.98, respectively), indicating that mHAP-II shows the
best prognostic performance in dynamic risk assessment
during repeated rounds of TACE (Table 5).
Discussion
In this multicenter study, we validated the prognostic value
of three HAP-related risk scores (HAP, mHAP, and
mHAP-II) before a first and second round of TACE in our
pooled patient population. The results demonstrated the
feasibility of dynamic risk assessment by sequential evalu-
ation of HAP-related risk scores over repeated TACE ses-
sions. mHAP-II score exhibited the greatest prognostic
accuracy in terms of homogeneity and discriminatory ability.
Based on these results, we propose an integrated algorithm
that includes sequential evaluation of mHAP-II score to
identify optimal candidates for TACE as the first-line treat-
ment modality and to determine the benefits of subsequent
TACE sessions. This algorithm may also facilitate the identi-
fication of subgroups of patients at risk of early treatment
failure over repeated TACE sessions (Fig. 3).
Our study has several strengths. First, the sample size
was large (n > 600), which enabled the assessment of the
prognostic performance of HAP-related risk scores after
sequential TACE sessions. Moreover, the follow-up dur-
ation was sufficient to perform a survival analysis, and >
70% of the patients died during the follow-up period,
which supports the validity of the HAP-related risk scores.
Finally, we focused on HAP-related risk scores, which use
several clinical characteristics obtained at the time of TACE.
In contrast to other risk-prediction scores, such as the
Table 2 Independent predictors of survival from a multivariate Cox proportional hazards model at the first and second rounds of
TACE
Variables At the first TACE At the second TACE
HR (95% CI) P value HR (95% CI) P value
Male gender 1.09 (0.86–1.38) 0.501 – –
Tumor size (cm) < 0.001 < 0.001
≤7 1 1
>7 1.90 (1.53–2.36) 1.91 (1.36–2.69)
Tumor number < 0.001 < 0.001
Unifocal 1 1
Multifocal 1.73 (1.43–2.09) 1.78 (1.45–2.19)
Alpha-fetoprotein (ng/mL) < 0.001 < 0.001
≤400 1 1
>400 1.58 (1.27–1.95) 2.31 (1.63–3.28)
Total bilirubin (mg/dL) 0.006 0.241
≤0.9 1 1
>0.9 1.31 (1.08–1.58) 1.14 (0.91–1.43)
Serum albumin (g/dL) < 0.001 0.004
≥3.6 1 1
<3.6 1.45 (1.19–1.77) 1.39 (1.11–1.75)
TACE; transarterial chemoembolization; HR, hazard ratio; CI, confidence interval
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STATE score, which incorporates C-reactive protein level (a
test not routinely performed in clinical practice [18]), these
simple-to-use risk-stratification strategies (sum of variables,
each worth one point) may be of use in HCC management.
In addition, sequential evaluation of HAP-related scores can
be performed from the first TACE session, and the time
interval between TACE sessions does not impact the results.
In contrast to the Assessment for Retreatment with TACE
(ART) score [19], these scores enable risk stratification in the
presence of metachronous HCC nodules and in cases in
which HCC treatment using TACE is insufficiently effective,
irrespective of the time interval between TACE sessions.
Previous studies have shown that radiological response
evaluation after TACE is a significant risk predictor in
HCC patients treated with TACE [4, 18, 19]. The ART
score uses radiological response based on EASL criteria
measured after TACE [19]. In addition, the SNACOR
model uses radiological responses based on mRECIST cri-
teria after TACE [4, 20]. Because the ART and SNACOR
models, which use post-TACE variables, were established
to identify candidates who would tolerate and benefit from
repeated TACE, not to identify candidates who should
start TACE as the first-line treatment, these models can-
not be used clinically to decide on TACE treatment initi-
ation. Although it is also important to perform TACE to
check tumor characteristics by evaluating the initial response
to TACE and to re-assess the long-term prognosis accord-
ingly, the chance of suboptimal response to the first TACE
treatment still remains, which may lead to poorer prognosis,
compared to pursuing other treatment modalities.
Meanwhile, because HAP-related risk scores do not in-
clude variables involved in treatment response and in
changes of liver function after TACE, they can be used start-
ing from the first TACE session. Thus, in a recent study that
proposed a sequential algorithm for selecting optimal candi-
dates for repeated TACE [21], HAP score was best suited for
screening patients prior to initial TACE, whereas sequential
use of ART score improved early detection of TACE failure.
However, the 90-day interval criterion, which is the basis of
establishing ART scores, was not adopted in this HAP-ART
sequential model. Furthermore, the combination of mHAP
and mHAP-II scores, instead of the conventional HAP score,
was not tested. Thus, further studies are warranted to com-
pare the predictive accuracy of different combination
Fig. 1 Kaplan-Meier survival curves of A-B vs. C-D class mHAP-II, mHAP, and HAP risk scores at the first (a-c) and second (d-f) rounds of TACE.
Patients with A-B class risk scores showed significantly better survival than those with C-D class risk scores at the first and second TACE rounds.
mHAP, modified hepatoma arterial-embolization prognostic; TACE, trans-arterial chemoembolization
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strategies using other models, such as the SNACOR model
without a time limitation between TACE sessions [20], as
well as mHAP [14] or mHAP-II [15].
Comparison of prognostic accuracy among HAP-related
risk scores has been considered controversial. While sev-
eral studies have validated their prognostic accuracy [14,
22], a comparison with mHAP-II scores was not available
in these studies. In other studies, the prognostic accuracy
of mHAP-II score was significantly better than that of
HAP score [15, 23]. Furthermore, the prognostic perform-
ance of mHAP score was unsatisfactory in comparison
with the mHAP-II or HAP scores [15]. When considering
Fig. 2 Kaplan-Meier survival curves of A-B vs. C-D class mHAP-II (a), mHAP (b), and HAP (c) risk scores at the second TACE among patients who
showed A-B class risk scores at the first TACE. Patients with A-B class risk scores showed significantly better survival than those with C-D class risk
scores at the second TACE. mHAP, modified hepatoma arterial-embolization prognostic; TACE, trans-arterial chemoembolization
Table 3 Survival outcomes according to risk scores at the first and second rounds of TACE
Risk scores Median
survival (95%
CI)
Survival rate Cox regression
1-year 3-years 5-years HR (95% CI) P value*
At the first TACE (n = 619)
mHAP-II
A-B (n = 283) 43.7 (36.8–50.6) 89.8% 59.7% 40.1% 1
C-D (n = 336) 21.5 (18.5–24.5) 65.7% 31.3% 16.8% 2.07 (1.71–2.50) <0.001
mHAP
A-B (n = 519) 35.2 (31.6–38.8) 83.6% 49.7% 30.8% 1
C-D (n = 100) 10.2 (8.3–12.1) 40.2% 15.5% 9.3% 2.73 (2.17–3.45) <0.001
HAP
A-B (n = 394) 39.8 (35.3–44.3) 86.1% 53.9% 34.1% 1
C-D (n = 225) 18.6 (14.2–23.0) 60.2% 27.4% 15.7% 2.01 (1.66–2.42) <0.001
At the second TACE (n = 514)
mHAP-II
A-B (n = 263) 38.6 (33.8–43.4) 86.5% 51.9% 33.3% 1
C-D (n = 251) 17.2 (14.9–19.5) 60.3% 24.2% 11.2% 2.28 (1.86–2.80) <0.001
mHAP
A-B (n = 441) 30.0 (26.6–33.4) 78.9% 42.6% 25.0% 1
C-D (n = 73) 8.5 (6.8–10.2) 39.4% 12.7% 7.0% 2.64 (2.02–3.44) <0.001
HAP
A-B (n = 337) 32.6 (27.8–37.4) 81.6% 46.5% 27.8% 1
C-D (n = 177) 17.2 (14.0–20.4) 57.5% 22.8% 12.3% 1.97 (1.60–2.41) <0.001
P value* indicates a comparison with A-B class of risk scores
HAP hepatoma arterial-embolization prognostic, mHAP modified HAP, CI confidence interval, TACE trans-arterial chemoembolization
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the prognostic significance of tumor number, which is in-
corporated into various HCC staging systems, such as
BCLC staging and that of the American Joint Committee
on Cancer (AJCC) [17, 24], as well as the association of
tumor multiplicity with incomplete response after the first
TACE and unfavorable long-term outcome [3], the inclu-
sion thereof in mHAP-II score may render it superior to
the HAP or mHAP scores. However, further validation
studies are still required.
Although a recent study showed that development of
progression or need for three rounds of TACE within the
first 6 months are predictive of TACE refractoriness with
anticipated poor outcomes [25], early optimization of
treatment strategies, even at baseline, using HAP-related
risk scores or after the first TACE (ART and SNACOR) is
warranted, rather than adhering to ineffective, repeated
TACE treatments. Indeed, mHAP-II score differs with
TACE-refractoriness in that it was established to identify
potential poor responders “before TACE,” whereas the
current concept of TACE-refractory was established based
on treatment responses “after several rounds of TACE.”
Thus, further studies are also required to identify potential
poor responders by modifying the discordant strategies. If
poor prognosis is anticipated, modifications of treatment
options, such as trans-arterial radioembolization, com-
bined therapy with sorafenib, or external radiotherapy, or
clinical trials can be considered.
This study had several limitations. First, the alternative
treatments used after unsatisfactory results of TACE during
the follow-up period might have influenced overall survival.
Second, because we compared the prognostic power of
HAP-related risk scores, we did not analyze other models
that use post-TACE variables (e.g., the ART and SNACOR
models). Thus, the predictive power of combinations of
pre-TACE and post-TACE variables need to be evaluated.
Third, TACE was performed during the study period even in
individuals with class C–D HAP-related risk scores at the
first and second TACE rounds due to the non-availability of
other treatment options; this might have influenced the re-
sults of the survival analysis. Finally, although we analyzed a
large sample from two institutions to increase statistical reli-
ability, inter-institutional variability, particularly with regard
Table 5 Prognostic accuracy of the sequential use of risk scores
during repeated TACE rounds to predict mortality
Risk scores Likelihood ratio (χ2) Linear trend (χ2) AIC
mHAP-II 22.61 24.43 1432.53
mHAP 14.67 19.67 3412.29
HAP 13.97 14.19 2296.98
The model with a higher χ2 value by the likelihood ratio test and the linear
trend test was considered the better model for homogeneity and
discriminatory ability. Furthermore, lower values for Akaike information criteria
were considered indicative of better discriminatory ability
AIC Akaike information criteria, mHAP modified hepatic
arterial-embolization prognostic
Table 4 Survival outcomes according to the sequential use of risk scores during repeated TACE rounds
Risk scores Median
survival (95%
CI)
Survival rate Cox regression
1-year 3-years 5-years HR (95% CI) P value*
mHAP-II (n = 619)
A-B at the first TACE (n = 283)
No second TACE (n = 55) – – – – – –
A-B at the second TACE (n = 185) 40.6 (36.6–44.6) 89.6% 58.6% 35.5% 1 –
C-D at the second TACE (n = 43) 19.6 (16.6–22.6) 66.8% 25.4% 16.4% 2.15 (1.48–3.12) <0.001
C-D at the first TACE (n = 336) 21.5 (18.5–24.5) 65.7% 31.3% 16.8% 2.31 (1.85–2.87) <0.001
mHAP (n = 619)
A-B at the first TACE (n = 519)
No second TACE (n = 82) – – – – – –
A-B at the second TACE (n = 412) 31.2 (27.5–34.9) 81.2% 44.6% 26.2% 1
C-D at the second TACE (n = 25) 16.9 (2.9–30.9) 56.0% 16.0% 8.0% 2.28 (1.49–3.48) <0.001
C-D at the first TACE (n = 100) 10.2 (8.3–12.1) 40.2% 15.5% 9.3% 2.91 (2.29–3.69) <0.001
HAP (n = 619)
A-B at the first TACE (n = 394)
No second TACE (n = 71) – – – – – –
A-B at the second TACE (n = 278) 35.8 (31.3–40.3) 84.6% 49.6% 30.0% 1
C-D at the second TACE (n = 45) 21.0 (15.0–27.0) 70.6% 23.9% 12.1% 1.84 (1.30–2.62) 0.001
C-D at the first TACE (n = 225) 48.6 (14.2–23.0) 60.2% 27.4% 15.7% 2.17 (1.77–2.66) <0.001
P value* indicate the comparison with A-B of risk scores at the first TACE
TACE trans-arterial chemoembolization, CI confidence interval, HR hazard ratio, mHAP modified hepatoma arterial-embolization prognostic
Park et al. BMC Cancer          (2019) 19:363 Page 8 of 10
to the TACE technique and baseline variables, might have
biased the results. To resolve this issue, a well-designed pro-
spective study with stratification using a predefined algo-
rithm based on mHAP-II score is needed to validate our
results. In addition, the reproducibility of the predictive
power of HAP-related risk scores after a third TACE session
and in patients of other ethnicities needs to be investigated.
Conclusions
In conclusion, we demonstrated the feasibility of dynamic
risk assessment by sequential evaluation of HAP-related risk
scores before a first and second round of TACE in patients
with HCC. Among HAP-related risk scores, mHAP-II score
showed superior performance for identifying patients who
would benefit from single and repeated TACE sessions. In
addition, we proposed an integrated algorithm including se-
quential evaluation of mHAP-II score to identify optimal
candidates for TACE as the first-line treatment modality and
to determine the benefits of subsequent TACE sessions. This
algorithm may also facilitate identification of subgroups of
patients at risk of early treatment failure during repeated
TACE sessions. Further studies should seek to investigate the
predictive performance of combinations of various, currently
available risk-prediction scores for the long-term outcomes
of patients with HCC undergoing repeated rounds of TACE.
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